SEATTLE, WA, USA I May 9, 2013 I Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.
Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors. Application of this technology is being explored in cells of cancer patients, to assess the impact of treatments on the immune system and evaluated as a tool to identify patient populations who might be more likely to respond to targeted therapies based on their immune status.
“We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents,” said Chad Robins, CEO and Founder of Adaptive Biotechnologies. “Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves.”
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation ( http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ ( http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ ( http://www.clonoseq.com), a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common tests. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.
SOURCE: Adaptive Biotechnologies
Post Views: 302
SEATTLE, WA, USA I May 9, 2013 I Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology.
Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput next-generation sequencing to characterize the repertoire of T and B cell receptors. Application of this technology is being explored in cells of cancer patients, to assess the impact of treatments on the immune system and evaluated as a tool to identify patient populations who might be more likely to respond to targeted therapies based on their immune status.
“We are delighted to collaborate with Bristol-Myers Squibb to help uncover immunological biomarkers of response to cancer agents,” said Chad Robins, CEO and Founder of Adaptive Biotechnologies. “Collaborating with Bristol-Myers Squibb is a real win for companies like ours that are committed to deepening the understanding of the interaction between the host immune system and the cancer cells themselves.”
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation ( http://www.adaptivebiotech.com), headquartered in Seattle, WA, is pioneering the field of genomic immunology. The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research and clinical communities as well as the biopharmaceutical industry. Adaptive operates a state-of-the-art high throughput centralized laboratory in Seattle that is CLIA certified and will be accepting clinical samples in 2013. Its flagship commercial product, immunoSEQ ( http://www.immunoSEQ.com), uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. In 2013, the company will introduce clonoSEQ ( http://www.clonoseq.com), a clinical assay to measure and monitor minimal residual disease (MRD) in a range of blood-based cancers that is significantly more sensitive than today’s most common tests. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface.
SOURCE: Adaptive Biotechnologies
Post Views: 302
